Compare Novartis AG (NVS) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance

Novartis AGTrade

First Trust NASDAQ 100 Technology Index FundTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while First Trust NASDAQ 100 Technology Index Fund trades at $310.02. The key difference: Novartis AG pays a 3.17% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals.

	NVS	QTEC
Market Cap	$290.25B	—
Sector	Health	Broad Market / Factor
52-Week High	$168.62	$335.74
52-Week Low	$113.50	$207.03
Enterprise Value	$330.27B	—
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

First Trust NASDAQ 100 Technology Index Fund

QTEC trades at $301.50, up 0.53% today, with a bearish technical signal overall. Key support lies at $298 and resistance at $302. The ETF provides equal-weighted exposure to top technology firms, tracking the Nasdaq-100 Technology Sector Index. Recent news highlights its broad tech sector focus and questions on AI and chip stock valuations.

Outlook remains tied to technology sector performance, with risks from market volatility and sector-specific headwinds. Investment opportunity lies in targeted tech exposure, but caution is warranted given overheated valuations in segments like AI.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

QTEC

View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About First Trust NASDAQ 100 Technology Index Fund

QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.